Betta Pharmaceuticals Co., Ltd.

Related records

Trials (85)

• A Food-Effect Study of BPI-16350 in Healthy Subjects
• A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors
• A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
• A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
• A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors
• A Phase I Study of BPI-16350 in Patients with Advanced Solid Tumor
• A Phase I Study of CFT8919 in Patients With Advanced NSCLC
• A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668
• A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
• A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma
• A Real World Study of Ensartinib in Advanced ALK-positive NSCLC
• A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer
• A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer
• A Study of BPI-452080 in Subjects With Solid Tumors
• A Study of BPI-460372 in Advanced Solid Tumor Patients
• A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
• A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy
• A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers
• A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.
• Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations